Dr. Lal PathLabs (LALPATHLAB) investor relations material

Executive summary

• FY 2026 delivered 12.2% year-over-year revenue growth, with Q4 marking the highest quarterly growth in 16 quarters, driven by strong volume momentum and patient preference for organized diagnostics.

• Network expanded with 14 new labs and over 1,100 collection centers, and integration of AI diagnostic tools and premium wellness offerings like Sovaaka.

• Preventive healthcare brand Swasthfit contributed 27% to FY 2026 revenue, with B2C share at 75%.

• Hosted Medllumina 2026 international medical conference, reinforcing scientific leadership.

• Audited standalone and consolidated financial results for FY26 were approved with unmodified audit opinions.

Financial highlights

• FY26 consolidated revenue reached INR 27,629 million (12.2% YoY growth); Q4 revenue was INR 703 crores (16.6% YoY growth).

• EBITDA before exceptional items grew 12.5% to INR 783 crores; normalized PAT rose 17.9% to INR 532 crores.

• EPS for FY26: INR 30.2 (basic, consolidated), up 3.4% YoY.

• Net cash and equivalents at year-end: INR 1,526 crores (operational), INR 2,428 million (consolidated financials).

• Final dividend of INR 4 per share, total INR 20.5 per share for FY26 (280% payout after bonus adjustment).

Outlook and guidance

• FY27 revenue growth guided at early to mid-teens (13–15%), with EBITDA margin expected to remain in the 27–28% range.

• CapEx guidance for FY27: INR 100–120 crores, including maintenance, new labs, and precision/radiology investments.

• Expansion into Mumbai via acquisition and international presence through Dubai subsidiary indicate growth focus.

• Continued investment in digital transformation, premium wellness, and precision medicine.

• No immediate price hikes planned; any increase will be considered after market assessment.